• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® TAG® CONFORMABLE THORACIC STENT GRAFT WITH ACTIVE CONTROL SYSTEM; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® TAG® CONFORMABLE THORACIC STENT GRAFT WITH ACTIVE CONTROL SYSTEM; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number TGM282815J
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Paralysis (1997)
Event Date 10/01/2023
Event Type  Injury  
Event Description
The following publication was reviewed by gore: title: a case in which aortic intimal sarcoma was diagnosed by tumor biopsy during stent graft implantation and early chemotherapy was performed source: the journal of japanese college of angiology 2023: 63(suppl.) p.S254.48 year old female.She visited the hospital complaining of lower back pain, and a metastatic bone tumor was suspected.A ct-guided biopsy diagnosed her with sarcoma.Contrast-enhanced ct revealed tumorous lesions with wall thickening in the thoracoabdominal aorta and its branch vessels, and aortic intimal sarcoma was suspected.A saccular aneurysm was also observed in the descending thoracic aorta.Stent graft insertion and biopsy of the intravascular neoplastic lesion were performed.Gore tag tgm282815j was deployed using a 22fr dry seal sheath.No endoleak was observed after touch-up.Thereafter, the dry seal sheath was placed near the tumor, and a biopsy was performed using biopsy forceps.After the procedure, the patient developed transient paraplegia, but it improved with blood transfusion, blood pressure control, and steroid pulse therapy, and she was discharged from the hospital on the 5th postoperative day.Postoperative pathology revealed aortic intimal sarcoma, with multiple bone metastases and liver metastases.The patient was admitted to the hospital on the 15th day after procedure, and medication treatment began on the 20th day.Currently, the tumor is not growing and is undergoing chemotherapy.
 
Manufacturer Narrative
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H3: code "other" was selected as the medical device was discarded at facility.Return not possible.H6: a review of the manufacturing records for the device could not be performed as a valid lot number was not provided.H6: according to the gore® tag® conformable thoracic stent graft with active control system instructions for use (ifu), potential adverse events or complications associated with the use of the device include, but are not limited to: neurologic damage, local or systemic (e.G., stroke, paraplegia, paraparesis).W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event Description
The following publication was reviewed by gore: title: a case in which aortic intimal sarcoma was diagnosed by tumor biopsy during stent graft implantation and early chemotherapy was performed source: the journal of japanese college of angiology 2023: 63(suppl.) p.S254.48 year old female.She visited the hospital complaining of lower back pain, and a metastatic bone tumor was suspected.A ct-guided biopsy diagnosed her with sarcoma.Contrast-enhanced ct revealed tumorous lesions with wall thickening in the thoracoabdominal aorta and its branch vessels, and aortic intimal sarcoma was suspected.A saccular aneurysm was also observed in the descending thoracic aorta.Stent graft insertion and biopsy of the intravascular neoplastic lesion were performed.Gore tag (b)(4) was deployed using a 22fr dry seal sheath.No endoleak was observed after touch-up.Thereafter, the dry seal sheath was placed near the tumor, and a biopsy was performed using biopsy forceps.After the procedure, the patient developed transient paraparesis, but it improved with blood transfusion, blood pressure control, and steroid pulse therapy, and she was discharged from the hospital on the 5th postoperative day.Postoperative pathology revealed aortic intimal sarcoma, with multiple bone metastases and liver metastases.The patient was admitted to the hospital on the 15th day after procedure, and medication treatment began on the 20th day.Currently, the tumor is not growing and is undergoing chemotherapy.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® TAG® CONFORMABLE THORACIC STENT GRAFT WITH ACTIVE CONTROL SYSTEM
Type of Device
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL WOODY SPRINGS B/P
3450 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
ayako yoshioka
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key18593022
MDR Text Key333897091
Report Number2017233-2024-04568
Device Sequence Number1
Product Code MIH
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P040043
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 03/29/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberTGM282815J
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 01/12/2024
Initial Date FDA Received01/28/2024
Supplement Dates Manufacturer Received01/12/2024
Supplement Dates FDA Received03/29/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age48 YR
Patient SexFemale
-
-